Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Tryptamine and dimethyltryptamine inhibit indoleamine 2,3 dioxygenase and increase the tumor-reactive effect of peripheral blood mononuclear cells

Full text
Author(s):
Tourino, Melissa Cavalheiro [1] ; de Oliveira, Edson Mendes [1] ; Belle, Luziane Potrich [1] ; Knebel, Franciele Hinterholz [1] ; Albuquerque, Renata Chaves [1] ; Doerr, Felipe Augusto [1] ; Okada, Sabrina Sayori [1] ; Migliorini, Silene [1] ; Soares, Irene Silva [1] ; Campa, Ana [1]
Total Authors: 10
Affiliation:
[1] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Clin Chem & Toxicol, BR-05508900 Sao Paulo - Brazil
Total Affiliations: 1
Document type: Journal article
Source: Cell Biochemistry and Function; v. 31, n. 5, p. 361-364, JUL 2013.
Web of Science Citations: 17
Abstract

Indoleamine 2,3-dioxygenase (IDO) is an interferon- (IFN-)-induced tryptophan-degrading enzyme, producing kynurenine (KYN) that participates in the mechanism of tumor immune tolerance. Thus, IDO inhibition has been considered a strategy for anticancer therapy. The aim of this study was to identify whether the metabolites originated from the competitive routes of tryptophan metabolism, such as the serotonergic or N, N-dimethyltryptamine (DMT) pathways, have inhibitory effects on recombinant human IDO (rhIDO) activity. Serotonin and melatonin had no effect; on the other hand, tryptamine (TRY) and DMT modulated the activity of rhIDO as classical non-competitive inhibitors, with Ki values of 156 and 506 M, respectively. This inhibitory effect was also observed on constitutively expressed or IFN--induced IDO in the A172 human glioma cell line. TRY and DMT increased the cytotoxic activity of peripheral blood mononuclear cells (PBMCs) in co-culture assays. We conclude that the IDO inhibition by TRY and DMT contributed to a more effective tumor-reactive response by the PBMCs. Copyright (c) 2013 John Wiley \& Sons, Ltd. (AU)

FAPESP's process: 09/14632-3 - Kynurenine versus serotonergic pathway: role in the cross talking of immune cells and in the immune escape of tumors
Grantee:Ana Campa
Support Opportunities: Regular Research Grants